Company
Every investor coverage indicates participated in a round Opthea raised.
Companies Opthea acquired or merged with, per published coverage. Buying a company is not investing in one: nothing here counts in the deals column.
| Name | Role | Sources |
|---|---|---|
| Fred Guerard | CEO | Forbes Australia |
| Megan Baldwin | Chief Innovation Officer | Forbes Australia |
Stories naming Opthea. Where several outlets covered the same round, they are bundled under whichever ran the fullest account.
Opthea's lead Phase-3 trial of its wet macular degeneration drug missed its endpoint, leaving the Australian biotech weighing its future and possible payouts to investors under its funding agreement.